Efficacy and safety of home treatment versus in hospital treatment with LMWH in patients with non-massive pulmonary embolism
- Conditions
- Pulmonary embolismHome treatmentLow-molecular-weight-heparinAnd in Dutch: LongembolieThuisbehandelingLaag-moleculair-gewicht-heparine
- Registration Number
- NL-OMON22733
- Lead Sponsor
- eiden University Medical Center, Department of General Internal Medicine-Endocrinology
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 260
1. Consecutive patients with proven acute non-massive, stable Pulmonary Embolism (PE), i.e. PE that does not warrant thrombolytic therapy, presenting to the emergency ward or to the outpatient clinic.
2. Patients with provoked and non-provoked (‘idiopathic’) pulmonary embolism and patient with a first as well as those with a recurrent episode of pulmonary embolism are considered eligible for the study.
1. Patients who have had symptoms of PE for longer than 7 days duration
2. Active bleeding, or a very high risk for major bleeding, i.e. gastro-intestinal bleeding in the preceding 14 days, recent stroke (less than 4 weeks ago), recent operation (less than 2 weeks ago), bleeding disorder, or thrombocytopenia (platelet count < 75 x 109/L)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method